The relationship of changes in molecular subtypes with metastases and progression-free survival in breast cancer

Author:

Amansyah Fitran1,Prihantono Prihantono1ORCID,Hamid Firdaus2ORCID,Syamsu Salman Ardi3ORCID,Pieter Jr. John3,Faruk Muhammad1ORCID

Affiliation:

1. , , Hasanuddin University, , Indonesia

2. , , , Indonesia

3. , , , Hasanuddin University, , Indonesia

Abstract

BACKGROUND: Molecular subtyping of breast cancer cells is increasingly being developed as an initial step in selecting therapy and predicting the prognosis of breast cancer patients. During breast cancer, the molecular subtype of cancer cells can change. This study aimed to analyze the relationship between changes in the intrinsic subtype of breast cancer with metastasis and progression-free survival in breast cancer patients. METHODS: This was a retrospective cohort study of patients diagnosed with breast cancer from 2016 to 2021. The molecular subtypes from the immunohistochemical examination results were recorded twice, and metastasis and progression-free survival (PFS) were recorded. The data were analyzed using the chi-square test and SPSS 26. RESULTS: Of the 44 patients, 19 (43.2%) experienced a change in molecular subtype, and 25 (56.8%) did not. No significant relationship existed between changes in molecular subtype and metastasis (p = 0.405). No significant relationship existed between changes in molecular subtype and PFS (p = 0.900). A significant relationship was found between changes in the molecular subtype and PFS in the patients with changes in the molecular subtype (p = 0.022). CONCLUSIONS: Changes in the intrinsic subtype were associated with PFS in breast cancer patients. Patients with an intrinsic subtype that changed to triple-negative showed worse PFS.

Publisher

IOS Press

Reference24 articles.

1. Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020;Lei;Cancer Communications,2021

2. Management of breast lesions by breast physicians in a heavily populated South Asian developing country;Badar;Asian Pacific J Cancer Prev,2011

3. Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma;Hotte;Curr Oncol,2011

4. Grading of invasive breast carcinoma: The way forward;van Dooijeweert;Virchows Arch,2022

5. Breast cancer intrinsic subtype classification, clinical use and future trends;Dai;Am J Cancer Res,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3